Table 1.
Whole cohort and SID/EID group characteristics
| Variables** |
TOTAL (n = 278) |
SID (n = 174) |
EID (n = 104) |
p value* |
|---|---|---|---|---|
| A-C interval duration (months) | 21 ± 12.2 | 10.3 ± 3.6 | 15.1 ± 2.5 | < 0.01 |
| Age | 43.2 ± 11.3 | 42.9 ± 11.7 | 43.6 ± 10.5 | 0.623 |
| Female, n (%) | 178(64) | 106 (60.9) | 72(69.2) | 0.204 |
| Disease duration (years) | 10.6 ± 7.5 | 9.7 ± 7 | 12.1 ± 7.9 | 0.011 |
| Naïve, n (%) | 51 (18.3) | 38 (21.8) | 13 (12.5) | 0.073 |
| N. of DMTs before OCR | 1.9 ± 1.5 | 1.8 ± 2.2 | 2.1 ± 1.6 | 0.073 |
| EDSS score before infusion A, median [IQR] (all) | 3.0 [2.0–6.0] | 3.0 [1.0–6.0] | 3.0 [2.0–6.0] | 0.411 |
|
Patients who relapsed in the year before infusion A, n (%) |
17 (6.1) | 11 (6.3) | 6 (5.8) | 0.942 |
| Patients with MRI activity in the year before infusion A, n (%) | 25 (8.9) | 14 (8) | 9 (8.7) | 0.962 |
| Time on OCR (from start to infusion A, months) | 29.2 ± 10.8 | 29.1 ± 12.1 | 29.2 ± 8.1 | 0.964 |
| Vaccination against SARS-CoV-2, n (%) | 122 (43.8) | 85 (48.9) | 67 (64.4) | 0.025 |
| Reasons for EID | ||||
| Concerns related to the risk of contracting COVID-19/lack of certain information about the consequences of COVID-19 and OCR therapy, n (%) | - | - | 70 (67.3) | |
| Delay due to vaccination against SARS-CoV-2, n (%) | - | - | 34 (32.7) | |
| CD19 + B-cell depletion before infusion A, n (%) | 139 (50) | 88 (50.6) | 51 (49) | 0.901 |
| CD19 + B-cell depletion before infusion B, n (%) | 182 (65.5) | 119 (68.4) | 63 (60.6) | 0.241 |
| CD19 + B-cell depletion before infusion C, n (%) | 179 (64.4) | 117 (67.2) | 62 (59.6) | 0.197 |
DMTs disease modifying therapies, EID extended interval dosing, EDSS expanded disability status scale; MRI, magnetic resonance imaging; N. number, OCR ocrelizumab, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
*via t test, Mann–Whitney U test or chi-squared test; **data are reported as the mean ± standard deviation unless otherwise specified. Statistically significant values are shown in bold